Biogen

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1978-01-01

Employees: 7.5K

Market Cap: $29.6B

Website: https://www.biogen.com

Introduction: Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Clinical Trials

A Study to Explore Pharmacodynamic Effects of BIIB104 on Brain Circuitry in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Placebo
Drug: BIIB104

First Posted Date: 2019-08-28

Last Posted Date: 2021-03-22

Lead Sponsor: Biogen

Target Recruit Count: 30

Registration Number: NCT04068532

Locations: 🇬🇧
Research Site, London, United Kingdom

Study to Evaluate DNL151 in Subjects With Parkinson's Disease

Phase 1

Completed

Conditions: Parkinson's Disease

Interventions: Drug: DNL151
Drug: Placebo

First Posted Date: 2019-08-14

Last Posted Date: 2023-04-18

Lead Sponsor: Biogen

Target Recruit Count: 36

Registration Number: NCT04056689

Locations: 🇳🇱
QPS, Leeuwarden, Netherlands
🇬🇧
Simbec-Orion Clinical Pharmacology, Merthyr Tydfil, United Kingdom
🇧🇪
UZ Leuven, Leuven, Belgium

and more 5 locations

A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive Disorder

Phase 3

Terminated

Conditions: Major Depressive Disorder

Interventions: Drug: SAGE-217
Drug: Placebo

First Posted Date: 2019-07-05

Last Posted Date: 2023-11-29

Lead Sponsor: Biogen

Target Recruit Count: 53

Registration Number: NCT04007367

Locations: 🇺🇸
Sage Investigational Site, Everett, Washington, United States

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease

Phase 1

Completed

Conditions: Parkinson's Disease

Interventions: Drug: BIIB094
Drug: Placebo

First Posted Date: 2019-06-06

Last Posted Date: 2025-04-27

Lead Sponsor: Biogen

Target Recruit Count: 62

Registration Number: NCT03976349

Locations: 🇪🇸
Laboratorios de Investigación Biocruces 3., Hospital de Cruces, Barakaldo, Bizkaia, Spain
🇺🇸
Northwestern University PD and Movement Disorders Center, Chicago, Illinois, United States
🇺🇸
The Cleveland Clinic Foundation, Cleveland, Ohio, United States

and more 14 locations

A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

Phase 3

Active, not recruiting

Conditions: Multiple Sclerosis, Relapsing-Remitting

Interventions: Drug: BIIB017 (peginterferon beta-1a)
Drug: Interferon beta type 1a

First Posted Date: 2019-05-22

Last Posted Date: 2024-08-22

Lead Sponsor: Biogen

Target Recruit Count: 142

Registration Number: NCT03958877

Locations: 🇧🇪
Clinique CHC MontLégia, Liege, Wallonia, Belgium
🇭🇷
Clinical Hospital Center 'Sestre Milosrdnice', Zagreb, Croatia
🇩🇪
St. Josef-Hospital Universitaetsklinikum, Bochum, Nordrhein Westfalen, Germany

and more 62 locations

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis

Phase 1

Completed

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: BIIB100
Drug: Placebo

First Posted Date: 2019-05-10

Last Posted Date: 2023-04-18

Lead Sponsor: Biogen

Target Recruit Count: 49

Registration Number: NCT03945279

Locations: 🇺🇸
Barrow Neurological Institute, Phoenix, Arizona, United States
🇺🇸
University of California San Diego Medical Center, San Diego, California, United States
🇺🇸
University of South Florida, Tampa, Florida, United States

and more 4 locations